MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1167/iovs.04-1076

Медицинская библиотека · Investigative ophthalmology & visual science · 2005

Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease.

Kim Hyuncheol, Csaky Karl G, Gilger Brian C, Dunn James P, Lee Susan S, Tremblay Marcus, de Monasterio Francisco, Tansey Ginger, Yuan Peng, Bungay Peter M, Lutz Robert J, Robinson Michael R

СтатьяПеревод в очереди

Аннотация

PURPOSE: To develop a local drug delivery system that provides therapeutic cyclosporine levels to treat lacrimal gland graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

METHODS

Episcleral cyclosporine implants were manufactured with a silicone-based matrix design, and in vitro release rates were determined. Preclinical evaluation included toxicology (clinical examination, serial electroretinography, and histopathology) in normal rabbits and dogs, pharmacokinetics in normal rabbits, and pharmacodynamics in a canine model of aqueous tear deficiency and keratoconjunctivitis sicca.

RESULTS

The cyclosporine implants showed sustained release of drug over time with in vitro assays. Histopathology showed normal ocular tissues in both dogs and rabbits 6 months after implantation. The cyclosporine implant produced lacrimal gland drug levels 1 to 2 log units higher than those reported with a variety of topical cyclosporine formulations and oral administration. The cyclosporine implant was effective in a canine model of keratoconjunctivitis sicca, with all animals able to discontinue topical cyclosporine and maintain normal Schirmer scores over a 6-month follow-up.

CONCLUSIONS

This preclinical evaluation showed that the episcleral cyclosporine implant was safe, delivered potentially therapeutic cyclosporine levels to the lacrimal gland, and showed efficacy in a clinically relevant model of keratoconjunctivitis sicca. The episcleral cyclosporine implant shows promise in reducing the morbidity associated with lacrimal gland graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. In addition, continuous release of cyclosporine in the subconjunctival space with the episcleral implant was an effective means of delivering drug to the ocular surface and may have potential in treating other ocular inflammatory diseases.

Для цитирования: Kim Hyuncheol, Csaky Karl G, Gilger Brian C, Dunn James P, Lee Susan S, Tremblay Marcus, de Monasterio Francisco, Tansey Ginger, Yuan Peng, Bungay Peter M, Lutz Robert J, Robinson Michael R. Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease.. Investigative ophthalmology & visual science. 2005. DOI: 10.1167/iovs.04-1076.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.